troglitazone has been researched along with Invasiveness, Neoplasm in 7 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer." | 9.10 | Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 5.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer." | 5.10 | Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| " In the present study, we examined whether PPARgamma is a possible target molecule for the prevention of cell growth and invasion by treatment with agonists (troglitazone, rosiglitazone) and antagonists (T0070907, GW9662) in four different hepatocellular carcinoma (HCC) cell lines." | 3.74 | A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. ( Baek, HA; Choi, HN; Chung, MJ; Jang, KY; Kim, KR; Lee, HJ; Moon, WS; Park, HS, 2007) |
| " In this report, we show that ATF3 mRNA and protein expression are up-regulated in HCT-116 human colorectal cancer cells following treatment with NSAIDs, troglitazone, diallyl disulfide, and resveratrol." | 3.73 | The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). ( Alston-Mills, B; Bottone, FG; Eling, TE; Ishibashi, M; Kim, JS; Moon, Y, 2005) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 1.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "PPARgamma ligands inhibit pancreatic cancer cell invasion, suggesting that these agents may represent novel strategies to treat pancreatic cancer." | 1.32 | Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. ( Evers, BM; Farrow, B; Hashimoto, K; Iwamura, T; O'Connor, KL, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, CH | 1 |
| Yeh, CL | 1 |
| Yeh, SL | 1 |
| Lin, ES | 1 |
| Wang, LY | 1 |
| Wang, YH | 1 |
| Burstein, HJ | 1 |
| Demetri, GD | 1 |
| Mueller, E | 1 |
| Sarraf, P | 1 |
| Spiegelman, BM | 1 |
| Winer, EP | 1 |
| Farrow, B | 1 |
| O'Connor, KL | 1 |
| Hashimoto, K | 1 |
| Iwamura, T | 1 |
| Evers, BM | 1 |
| Motomura, W | 1 |
| Nagamine, M | 1 |
| Tanno, S | 1 |
| Sawamukai, M | 1 |
| Takahashi, N | 1 |
| Kohgo, Y | 1 |
| Okumura, T | 1 |
| Bottone, FG | 1 |
| Moon, Y | 1 |
| Kim, JS | 1 |
| Alston-Mills, B | 1 |
| Ishibashi, M | 1 |
| Eling, TE | 1 |
| Coras, R | 1 |
| Hölsken, A | 1 |
| Seufert, S | 1 |
| Hauke, J | 1 |
| Eyüpoglu, IY | 1 |
| Reichel, M | 1 |
| Tränkle, C | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Blümcke, I | 1 |
| Hahnen, E | 1 |
| Kim, KR | 1 |
| Choi, HN | 1 |
| Lee, HJ | 1 |
| Baek, HA | 1 |
| Park, HS | 1 |
| Jang, KY | 1 |
| Chung, MJ | 1 |
| Moon, WS | 1 |
1 trial available for troglitazone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chromans; Disease Progre | 2003 |
6 other studies available for troglitazone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Quercetin metabolites inhibit MMP-2 expression in A549 lung cancer cells by PPAR-γ associated mechanisms.
Topics: A549 Cells; Anilides; Animals; Anticarcinogenic Agents; Cell Movement; Chromans; Dietary Supplements | 2016 |
Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Topics: Chromans; Humans; Integrins; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Pancreatic | 2003 |
Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells.
Topics: Actins; Antineoplastic Agents; Cell Migration Inhibition; Cell Movement; Chromans; Culture Media, Co | 2004 |
The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3).
Topics: Activating Transcription Factor 3; Allyl Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2005 |
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chromans; DNA Primers; Dow | 2007 |
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Topics: Anilides; Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Proce | 2007 |